Exchange Traded Concepts LLC Acquires 12,328 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO)

Exchange Traded Concepts LLC boosted its holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO) by 25.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 60,675 shares of the company’s stock after acquiring an additional 12,328 shares during the quarter. Exchange Traded Concepts LLC’s holdings in Allogene Therapeutics were worth $170,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in ALLO. Perceptive Advisors LLC bought a new stake in Allogene Therapeutics in the second quarter valued at about $6,349,000. Lynx1 Capital Management LP bought a new stake in Allogene Therapeutics during the second quarter worth about $5,192,000. Price T Rowe Associates Inc. MD grew its stake in Allogene Therapeutics by 76.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 4,177,619 shares of the company’s stock worth $18,675,000 after buying an additional 1,806,147 shares during the last quarter. Renaissance Technologies LLC grew its stake in Allogene Therapeutics by 340.4% during the second quarter. Renaissance Technologies LLC now owns 1,747,955 shares of the company’s stock worth $4,073,000 after buying an additional 1,351,055 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in Allogene Therapeutics by 24.8% during the second quarter. Dimensional Fund Advisors LP now owns 2,550,640 shares of the company’s stock worth $5,944,000 after buying an additional 507,021 shares during the last quarter. Institutional investors own 83.63% of the company’s stock.

Analysts Set New Price Targets

ALLO has been the topic of several research analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $9.00 price objective on shares of Allogene Therapeutics in a research note on Thursday, August 15th. Canaccord Genuity Group decreased their price objective on shares of Allogene Therapeutics from $35.00 to $14.00 and set a “buy” rating on the stock in a research note on Thursday, August 8th. Citigroup upped their price objective on shares of Allogene Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Oppenheimer assumed coverage on shares of Allogene Therapeutics in a research note on Thursday, August 8th. They set an “outperform” rating and a $11.00 price objective on the stock. Finally, Truist Financial reissued a “buy” rating and set a $14.00 price target (down from $17.00) on shares of Allogene Therapeutics in a research note on Friday, August 9th. Three analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, Allogene Therapeutics has an average rating of “Moderate Buy” and an average price target of $9.96.

Allogene Therapeutics Price Performance

ALLO opened at $2.80 on Tuesday. The company’s 50 day simple moving average is $2.65 and its 200-day simple moving average is $2.75. Allogene Therapeutics, Inc. has a one year low of $2.01 and a one year high of $5.78. The stock has a market capitalization of $585.20 million, a P/E ratio of -1.56 and a beta of 0.83.

Allogene Therapeutics (NASDAQ:ALLO) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.03. Allogene Therapeutics had a negative net margin of 223,139.98% and a negative return on equity of 50.24%. As a group, analysts anticipate that Allogene Therapeutics, Inc. will post -1.38 EPS for the current year.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).